Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andes Virus DNA Vaccine Phase 1 Trial
NCT03682107Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2019
- Primary completion
- Sep 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Andes virus DNA vaccine in hantavirus pulmonary syndrome (HPS) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Experiencing Clinical Safety Laboratory Adverse Events at Day 176, Number of Participants Reporting Serious Adverse Events (SAEs) and 2 more. Started Feb 2019; status: completed.
02
Drugs
Andes virus DNA vaccine
03
Conditions
hantavirus pulmonary syndrome (HPS)
Beyond the preview
Go deeper on NCT03682107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682107.